Immune Checkpoints

Medulloblastoma (MB) is one of the most common pediatric brain cancers, accounting for approximately 20% of all primary brain tumors in children. Despite available treatments, about 30% of patients do not achieve a cure, and survivors often face significant long-term impairments in their quality of life. While immune checkpoint inhibition presents a promising avenue for targeted therapy, its potential in MB remains largely unexplored.

This study aims to investigate the efficacy of dual immune checkpoint inhibition as a novel therapeutic strategy for MB. We employ single-cell and single-nuclei sequencing of primary MB tumors, established Group 3 and Sonic Hedgehog MB cell lines, patient-derived xenograft (PDX) organoid models, and primary MB tissue from patients across all subtypes to explore immune checkpoint expression and the impact of their blockade in targeting MB.